Molecular Hydrogen Therapy Enhances Immune Markers in Treg, Plasma, Tr1 Cells, and KLRG1 Expression on Tc Cells: A Case of Acute SDH With Midline Shift and Uncal Herniation Post-decompressive Craniectomy
This case suggests that molecular hydrogen therapy may be a helpful adjunct treatment for SDH with midline shift. Conventional therapies, including craniectomy, hyperbaric oxygen, therapeutic hypothermia, and stem cell therapy, were vital to the patient's recovery, but hydrogen therapy may have contributed by modulating immune responses, particularly Treg and plasma cell activity. While these findings are encouraging, further research is necessary to confirm hydrogen therapy's benefits and its role alongside traditional neurocritical care treatments.
Authors
- Dueng‐Yuan Hueng (ORCID: https://orcid.org/0000-0001-7868-3161)
- Yi‐Jung Ho (ORCID: https://orcid.org/0009-0006-3931-2302)
- SHAN-WEN LUI (ORCID: https://orcid.org/0009-0002-1151-6814)
- KUANG-YIH WANG
- Jeng‐Wei Lu (ORCID: https://orcid.org/0000-0003-2128-2046)
- Feng‐Cheng Liu (ORCID: https://orcid.org/0000-0003-1291-8946)
- Ronghang Hu (ORCID: https://orcid.org/0009-0001-6515-2529)
- Hanqing Liu (ORCID: https://orcid.org/0000-0001-7984-6305)
- H. Hsu
- TING-YU HSIEH
Institutions
- University of Copenhagen (DK)
- Tri-Service General Hospital (TW)
- Rigshospitalet (DK)
- National Defense Medical Center (TW)
Publication Details
- Journal
- In Vivo
- Published
- 2025-02-26
- DOI
- https://doi.org/10.21873/invivo.13923
- Citations
- 2
- Primary Topic
- Hydrogen's biological and therapeutic effects
- Type
- article
- Field-Weighted Citation Impact
- 4.01
Funders
- Ministry of Science and Technology, Taiwan
- Tri-Service General Hospital
- National Science and Technology Council